(ZBH) Zimmer Biomet Holdings - Ratings and Ratios
Knee, Hip, Sports, Trauma, Orthopedic Products
ZBH EPS (Earnings per Share)
ZBH Revenue
Description: ZBH Zimmer Biomet Holdings
Zimmer Biomet Holdings Inc (NYSE:ZBH) is a global medical technology company that designs, manufactures, and markets a wide range of orthopedic reconstructive products and solutions. The companys product portfolio includes knee and hip replacement products, sports medicine, biologics, and craniomaxillofacial and thoracic products, among others. These products are used to treat patients with disorders or injuries to bones, joints, or supporting soft tissues.
From a market perspective, ZBH has a market capitalization of approximately $18.6 billion, indicating a significant presence in the healthcare equipment industry. The companys return on equity (ROE) is around 7.31%, suggesting a relatively stable financial performance. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be analyzed. For instance, ZBHs revenue growth has been driven by its diversified product portfolio and global presence. Additionally, the companys gross margin has been influenced by its ability to maintain a competitive pricing strategy and manage production costs effectively.
In terms of valuation, ZBHs price-to-earnings (P/E) ratio is around 20.84, indicating a moderate valuation compared to its earnings. The forward P/E ratio is approximately 11.79, suggesting a potential decrease in valuation in the future. To gain a deeper understanding of the companys valuation, metrics such as enterprise value-to-EBITDA (EV/EBITDA) and price-to-book (P/B) ratio can be examined. These metrics can provide insights into ZBHs capital structure and profitability.
From a trading perspective, ZBHs stock price has been relatively stable, with a 20-day simple moving average (SMA) of $93.15 and a 50-day SMA of $93.26. The stocks average true range (ATR) is around 1.97, indicating a moderate level of volatility. To further analyze the stocks price movement, indicators such as relative strength index (RSI) and Bollinger Bands can be used to identify potential trading opportunities.
ZBH Stock Overview
| Market Cap in USD | 19,635m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2001-07-25 |
ZBH Stock Ratings
| Growth Rating | -37.3% |
| Fundamental | 65.6% |
| Dividend Rating | 47.3% |
| Return 12m vs S&P 500 | -19.9% |
| Analyst Rating | 3.45 of 5 |
ZBH Dividends
| Dividend Yield 12m | 1.18% |
| Yield on Cost 5y | 0.93% |
| Annual Growth 5y | 0.59% |
| Payout Consistency | 97.1% |
| Payout Ratio | 12.1% |
ZBH Growth Ratios
| Growth Correlation 3m | 79.9% |
| Growth Correlation 12m | -53.7% |
| Growth Correlation 5y | -73.2% |
| CAGR 5y | -2.42% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.12 |
| Sharpe Ratio 12m | 0.38 |
| Alpha | 0.00 |
| Beta | 0.978 |
| Volatility | 22.86% |
| Current Volume | 1637.1k |
| Average Volume 20d | 1168.4k |
| Stop Loss | 96.9 (-3%) |
| Signal | 0.24 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (823.4m TTM) > 0 and > 6% of Revenue (6% = 470.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.05% (prev 13.70%; Δ 16.35pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.66b > Net Income 823.4m (YES >=105%, WARN >=100%) |
| Net Debt (7.02b) to EBITDA (2.28b) ratio: 3.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (198.3m) change vs 12m ago -3.92% (target <= -2.0% for YES) |
| Gross Margin 71.06% (prev 71.78%; Δ -0.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 35.30% (prev 34.97%; Δ 0.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.72 (EBITDA TTM 2.28b / Interest Expense TTM 261.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.79
| (A) 0.10 = (Total Current Assets 5.05b - Total Current Liabilities 2.70b) / Total Assets 22.87b |
| (B) 0.50 = Retained Earnings (Balance) 11.34b / Total Assets 22.87b |
| (C) 0.06 = EBIT TTM 1.23b / Avg Total Assets 22.19b |
| (D) 1.07 = Book Value of Equity 11.05b / Total Liabilities 10.33b |
| Total Rating: 3.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.64
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 5.34% = 2.67 |
| 3. FCF Margin 18.18% = 4.54 |
| 4. Debt/Equity 0.60 = 2.32 |
| 5. Debt/Ebitda 3.33 = -2.16 |
| 6. ROIC - WACC (= -1.62)% = -2.02 |
| 7. RoE 6.62% = 0.55 |
| 8. Rev. Trend 77.52% = 5.81 |
| 9. EPS Trend 48.38% = 2.42 |
What is the price of ZBH shares?
Over the past week, the price has changed by -2.33%, over one month by -2.57%, over three months by +11.05% and over the past year by -5.08%.
Is Zimmer Biomet Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZBH is around 95.06 USD . This means that ZBH is currently overvalued and has a potential downside of -4.86%.
Is ZBH a buy, sell or hold?
- Strong Buy: 5
- Buy: 6
- Hold: 16
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ZBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.9 | 11% |
| Analysts Target Price | 110.9 | 11% |
| ValueRay Target Price | 104.9 | 4.9% |
Last update: 2025-09-18 04:44
ZBH Fundamental Data Overview
CCE Cash And Equivalents = 556.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 24.1756
P/E Forward = 11.5875
P/S = 2.5065
P/B = 1.5677
P/EG = 1.0259
Beta = 0.682
Revenue TTM = 7.83b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 2.28b USD
Long Term Debt = 6.75b USD (from longTermDebt, last quarter)
Short Term Debt = 820.0m USD (from shortTermDebt, last quarter)
Debt = 7.57b USD (Calculated: Short Term 820.0m + Long Term 6.75b)
Net Debt = 7.02b USD (from netDebt column, last quarter)
Enterprise Value = 26.65b USD (19.64b + Debt 7.57b - CCE 556.9m)
Interest Coverage Ratio = 4.72 (Ebit TTM 1.23b / Interest Expense TTM 261.7m)
FCF Yield = 5.34% (FCF TTM 1.42b / Enterprise Value 26.65b)
FCF Margin = 18.18% (FCF TTM 1.42b / Revenue TTM 7.83b)
Net Margin = 10.51% (Net Income TTM 823.4m / Revenue TTM 7.83b)
Gross Margin = 71.06% ((Revenue TTM 7.83b - Cost of Revenue TTM 2.27b) / Revenue TTM)
Tobins Q-Ratio = 2.41 (Enterprise Value 26.65b / Book Value Of Equity 11.05b)
Interest Expense / Debt = 1.05% (Interest Expense 79.3m / Debt 7.57b)
Taxrate = 12.68% (131.4m / 1.04b)
NOPAT = 1.08b (EBIT 1.23b * (1 - 12.68%))
Current Ratio = 1.87 (Total Current Assets 5.05b / Total Current Liabilities 2.70b)
Debt / Equity = 0.60 (Debt 7.57b / last Quarter total Stockholder Equity 12.53b)
Debt / EBITDA = 3.33 (Net Debt 7.02b / EBITDA 2.28b)
Debt / FCF = 5.32 (Debt 7.57b / FCF TTM 1.42b)
Total Stockholder Equity = 12.44b (last 4 quarters mean)
RoA = 3.60% (Net Income 823.4m, Total Assets 22.87b )
RoE = 6.62% (Net Income TTM 823.4m / Total Stockholder Equity 12.44b)
RoCE = 6.43% (Ebit 1.23b / (Equity 12.44b + L.T.Debt 6.75b))
RoIC = 5.58% (NOPAT 1.08b / Invested Capital 19.32b)
WACC = 7.20% (E(19.64b)/V(27.21b) * Re(9.62%)) + (D(7.57b)/V(27.21b) * Rd(1.05%) * (1-Tc(0.13)))
Shares Correlation 3-Years: -81.82 | Cagr: -0.53%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.87% ; FCFE base≈1.30b ; Y1≈1.24b ; Y5≈1.19b
Fair Price DCF = 82.47 (DCF Value 16.34b / Shares Outstanding 198.1m; 5y FCF grow -6.20% → 3.0% )
EPS Correlation: 48.38 | EPS CAGR: 10.32% | SUE: 3.79 | # QB: 1
Revenue Correlation: 77.52 | Revenue CAGR: 8.26% | SUE: 1.31 | # QB: 1
Additional Sources for ZBH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle